The oral Janus kinase 1 (JAK1) inhibitor abrocitinib reduced signs and symptoms of atopic
dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose …

Aims Abrocitinib is a selective Janus kinase 1 inhibitor for the treatment of moderate‐to‐
severe atopic dermatitis. Herein we describe the time‐course of drug‐induced platelet …

Introduction Early prediction of abrocitinib efficacy in atopic dermatitis (AD) could help
identify candidates for an early dose increase. A predictive model determined week 12 …

Abstract Background and Objective Abrocitinib is a Janus kinase 1 inhibitor in development
for the treatment of atopic dermatitis (AD). This work characterized orally administered …

Abrocitinib, an oral once‐daily Janus kinase 1 selective inhibitor, is under development for
treatment of atopic dermatitis. This phase 1, nonrandomized, open‐label, single‐dose study …

Abrocitinib, an oral once‐daily Janus kinase 1 selective inhibitor, is under development for
the treatment of atopic dermatitis. This phase 1, nonrandomized, open‐label, single‐dose …

Introduction Atopic dermatitis (AD) is the most common inflammatory skin disorder. Despite
the high disease burden, the therapeutic options are limited and their efficacy in controlling …

Abrocitinib is an oral once-daily Janus kinase 1 selective inhibitor being developed for the
treatment of moderate-to-severe atopic dermatitis. This study examined the disposition of …

Background Pivotal phase III studies demonstrated that abrocitinib, an oral, once-daily, JAK1-
selective inhibitor, is effective treatment for moderate-to-severe atopic dermatitis (AD) as …

Importance Atopic dermatitis is associated with substantial patient and caregiver burden.
Currently available treatments for atopic dermatitis are inadequate or contraindicated for …